Table 1.
Baseline characteristics
sCAA, all 82 |
sCAA ICH + 23 |
sCAA ICH- 59 |
D-CAA, all 56 |
D-CAA symptomatic 25 |
D-CAA presymptomatic 31 |
Control 43 |
|
---|---|---|---|---|---|---|---|
Age, years, mean(SD) | 72 (6) | 71 (6) | 72 (6) | 52 (11) | 60 (8) | 46 (10) | 69 (9) |
Men, n(%) | 46 (56) | 15 (65) | 31 (53) | 26 (46) | 13 (52) | 13 (42) | 24 (56) |
Educational level, n(%) | |||||||
Low | 28 (34) | 5 (22) | 23 (39) | 14 (25) | 9 (36) | 5 (16) | 8 (19) |
Average | 21 (26) | 8 (33) | 13 (22) | 20 (36) | 5 (20) | 15 (48) | 11 (26) |
High | 27 (33) | 8 (33) | 19 (33) | 16 (29) | 8 (32) | 8 (26) | 21 (49) |
MoCa, mean(SD) | 24 (5) | 25 (4) | 24 (6) | 27 (3) | 26 (3) | 27 (2) | 27 (2) |
Medical History, n(%) | |||||||
Symptomatic ICH* | 23 (28) | 23 (100) | - | 25 (45) | 25 (100) | - | - |
Cognitive decline | 33 (40) | 7 (30) | 26 (44) | 13 (23) | 9 (36) | 4 (13) | - |
Hypertension | 44 (54) | 12 (52) | 32 (54) | 13 (23) | 6 (24) | 7 (23) | 19 (44) |
Hypercholesterolemia | 43 (52) | 15 (65) | 28 (48) | 6 (11) | 4 (16) | 2 (7) | 13 (30) |
Diabetes Mellitus | 5 (6) | 1 (4) | 4 (7) | 2 (4) | 1 (4) | 1 (3) | 5 (12) |
Depression | 3 (4) | 0 (0) | 3 (5) | 8 (14) | 3 (12) | 5 (16) | 1 (2) |
Time since last ICH†, years, median[IQR] | 2 [1,4] | 2 [1,4] | - | 3 [1,4] | 3 [1,4] | - | - |
Previous symptomatic ICH count, median[IQR] | 0 [0,1] | 1 [1,1] | - | 0 [0,1] | 1 [1,2] | - | - |
ICH in limbic regions of the brain§, n(% of all ICH) | 2 (6) | 2 (6) | - | 10 (23) | 10 (23) | - | - |
D-CAA Dutch-type cerebral amyloid angiopathy; sCAA sporadic CAA; ICH intracerebral hemorrhage; MoCA Montreal Cognitive Assessment
* Location % frontal/parietal/temporal/occipital: sCAA 38/29/15/21; D-CAA 30/21/21/35
§ Orbito-frontal cortex, cingulate cortex or anterior temporal lobe; Basal ganglia (ventral striatum), hippocampus, amygdala and fornix by definition not possible in CAA due to strictly lobar ICH
† Recorded only for patients with history of symptomatic ICH
Educational level missing in n = 2 sCAA-ICH+, n = 4 sCAA ICH-, n = 3 symptomatic D-CAA/presymptomatic D-CAA/controls